ATP production promoter

Abstract

To provide an ATP production promoter useful for preventing or treating diseases associated with decreased ATP production, particularly renal impairment. [Solution] The present invention comprises an ATP production promoter containing a component having URAT1 inhibitory activity. Preferably, the component having URAT1 inhibitory activity is at least one selected from the group consisting of benzbromarone, probenecid, dotinurad, recinurad, and berinurad. The present invention is expected to be useful as a preventive and therapeutic agent for diseases of decreased ATP production, and is particularly useful as a therapeutic and / or preventive agent for nephrotic syndrome, chronic glomerulonephritis, chronic tubulointerstitial nephritis, chronic pyelonephritis, amyloid kidney, familial juvenile hyperuricemia nephropathy, autosomal dominant tubulointerstitial kidney disease, nephronoplasia, renovascular hypertension, renal vein thrombosis, renal arteriovenous fistula, renal tubular acidosis, Gitelman syndrome, Bartter syndrome, Fanconi syndrome, Lowe syndrome, Alport syndrome, kidney and ureteral stones, and chronic renal failure.

Claims

1. An ATP production promoter containing an ingredient that inhibits URAT1 activity.

2. The ATP production promoter according to claim 1, wherein the component having URAT1 inhibitory activity is at least one selected from the group consisting of benzbromarone, probenecid, dotinurad, recinurad, and berinurad.

3. An ATP production promoter according to claim 2, for the treatment or prevention of diseases that reduce ATP production.

4. The ATP production promoter according to claim 3, wherein the disease causing decreased ATP production is at least one selected from the group consisting of kidney disease, liver disease, heart disease, diabetic metabolic disease, ischemic reperfusion injury, mitochondrial disease, neurological disease, musculoskeletal disease, skin disease, ophthalmic disease, and age-related disease.

5. The ATP production promoter according to claim 4, wherein the kidney disease is a chronic kidney disease.

6. The ATP production promoter according to claim 5, wherein the chronic kidney disease is at least one selected from the group consisting of nephrotic syndrome, chronic glomerulonephritis, chronic tubulointerstitial nephritis, chronic pyelonephritis, amyloid kidney, familial juvenile hyperuricemia, autosomal dominant tubulointerstitial kidney disease, nephronophthria, renovascular hypertension, renal vein thrombosis, renal arteriovenous fistula, renal tubular acidosis, Gitelman syndrome, Bartter syndrome, Fanconi syndrome, Lowe syndrome, Alport syndrome, kidney and ureteral stones, and chronic renal failure.

7. An ATP production promoter according to any one of claims 1 to 6, for oral administration.

8. The ATP production promoter according to claim 7, which is a pharmaceutical composition.

9. A pharmaceutical product comprising the pharmaceutical composition described in claim 8.

Images